Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Preemption of aGVHD
NCT06075225Phase 2Not yet recruiting
- Sponsor
- Sichuan University
- Start
- Oct 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Sichuan University. Primary endpoint: Incidence of Grade III or IV Acute Graft-versus-host Disease at Day 100. Planned start Oct 2023; status: not yet recruiting.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06075225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06075225.